Cambodia Pharmaceuticals & Healthcare Report

Published 01 April 2015

  • 81 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Cambodia Pharmaceuticals & Healthcare Report

BMI View: Despite improvements to the healthcare sector, high out of pocket expenditure means that access to healthcare will remain a challenging issue in Cambodia. Further investments in the sector will boost overall care quality and boost investments into the pharmaceutical sector.

Headline Expenditure Projections

  • Pharmaceuticals: KHR910.8bn (USD228mn) in 2014 to KHR10007.2bn (USD252mn) in 2015; +10.6% in local currency terms and US dollar terms. Forecast remains unchanged from previous quarter.

  • Healthcare: KHR5,119.8bn (USD1.3mn) in 2014 to KHR5,676.2bn (USD1.4mn) in 2015; +10.9% in local currency terms US dollar terms. Forecast upgraded due to new data from the World Health Organization.

Risk/Reward Index

Cambodia's Pharmaceutical Risk/Reward Index score for Q315 is 33.1 out of the maximum 100. The country scored below average for almost all indicators and sub-indicators including overall market expenditure, sector value growth and pensionable population. Consequently, with this low score, Cambodia ranks second-to-last out of the 19 key markets in Asia Pacific, ahead of Myanmar. Cambodia mainly suffers from Low per capita consumption, stemming from low wages, the absence of a national health insurance scheme and the wider lack of government financing in the country, poor intellectual property protection and cumbersome bureaucracy.

Key Trends And Developments

  • In June 2015, the country announced its first National Policy and Strategic Plan to Combat Antimicrobial Resistance. Dr Ly Sovann, director of Cambodia's Communicable Diseases Control Department stated that poor communication and collaboration between ministries, extensive use of antibiotics in farms and inadequate management of health resources are some challenges the country faces.

  • In April 2015, Cambodia's anti-economic crime police seized more than 100,000 boxes of illicit medicines including treatment for diabetes and weight-loss drugs.

BMI Economic View

Renewed political stability...

Table of Contents

BMI Industry View
7
SWOT
9
SWOT
11
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2011-2019)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019)
18
Pharmaceutical Trade Forecast
19
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2013-2019)
21
Key Risks To BMI's Forecast Scenario
21
Macroeconomic Forecasts
22
Economic Activity
22
Industry Risk Reward Ratings
25
Asia Pacific Risk/Reward Index
25
Cambodia Risk/Reward Index
31
Rewards
31
Risks
31
Market Overview
33
Industry Trends And Developments
35
Epidemiology
35
Healthcare Sector
37
Health Insurance
38
Research & Development
39
Clinical Trials
40
Regulatory Development
41
Regulatory Regime
41
Intellectual Property Issues
41
Counterfeit Medicines
42
Pricing And Reimbursement
44
Competitive Landscape
45
Pharmaceutical Sector
45
Company Developments
47
Pharmaceutical Wholesale
48
Pharmaceutical Retail
48
Company Profile
50
PharmaProduct Manufacturing (PPM)
50
Cambodia Pharmaceutical Enterprise
53
Sanofi
55
Pfizer
58
Demographic Forecast
60
Table: Population Headline Indicators (Cambodia 1990-2025)
61
Table: Key Population Ratios (Cambodia 1990-2025)
61
Table: Urban/Rural Population & Life Expectancy (Cambodia 1990-2025)
62
Table: Population By Age Group (Cambodia 1990-2025)
62
Table: Population By Age Group % (Cambodia 1990-2025)
63
Demographic Forecast
64
Table: Population Headline Indicators (Laos 1990-2025)
66
Table: Key Population Ratios (Laos 1990-2025)
66
Table: Urban/Rural Population & Life Expectancy (Laos 1990-2025)
67
Table: Population By Age Group (Laos 1990-2025)
67
Table: Population By Age Group % (Laos 1990-2025)
68
Demographic Forecast
69
Table: Population Headline Indicators (Myanmar 1990-2025)
70
Table: Key Population Ratios (Myanmar 1990-2025)
70
Table: Urban/Rural Population & Life Expectancy (Myanmar 1990-2025)
71
Table: Population By Age Group (Myanmar 1990-2025)
71
Table: Population By Age Group % (Myanmar 1990-2025)
72
Glossary
74
Methodology
76
Pharmaceutical Expenditure Forecast Model
76
Healthcare Expenditure Forecast Model
76
Notes On Methodology
77
Risk/Reward Index Methodology
78
Index Overview
79
Table: Pharmaceutical Risk/Reward Index Indicators
79
Indicator Weightings
80

The Cambodia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Cambodia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Cambodia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Cambodia, to test other views - a key input for successful budgeting and strategic business planning in the Cambodian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Cambodian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Cambodia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc